We hereby have identified CRABP-II as a novel player in pancreatic cancer lipid metabolism, and our observation that CRABP-II is overexpressed in PDAC but not detectable in normal pancreas and chronic pancreatitis justifies CRABP-II as a viable cancer selective target for PDAC therapy. This evidence concerns the gene CRABP2 and familial pancreatic carcinoma.